Zoetis (ZTS) Stock May Be Undervalued After FDA Approval News

What happened: Zoetis received FDA approval of Convenia RTU for Dogs, adding a product to its companion animal line. The article examines whether $ZTS shares are undervalued after the approval news. Key numbers: $ZTS has fallen 61.0% over the past 5 years. Why it matters: The article says the approval may support expectations for future revenue and profitability from the companion animal portfolio. It also says the P/E discount comes despite a fresh contributor to earnings being in the mix. Market: -0.6% today ($77.80), -37.7% YTD, 0.7x vol — as of 21:17 UTC

Zoetis received FDA approval of Convenia RTU for Dogs, adding a product to its companion animal line. The article examines whether $ZTS shares are undervalued after the approval news.

The article says the approval may support expectations for future revenue and profitability from the companion animal portfolio. It also says the P/E discount comes despite a fresh contributor to earnings being in the mix. Market: -0.6% today ($77.80), -37.7% YTD, 0.7x vol — as of 21:17 UTC